Purpose of review Cystic kidney diseases are common renal disorders characterized by the formation of fluid-filled epithelial cysts in the kidneys. The progressive growth and expansion of the renal cysts replace existing renal tissue within the renal parenchyma, leading to reduced renal function. While several genes have been identified in association with inherited causes of cystic kidney disease, the molecular mechanisms that regulate these genes in the context of post-transcriptional regulation are still poorly understood. There is increasing evidence that microRNA (miRNA) dysregulation is associated with the pathogenesis of cystic kidney disease.
INTRODUCTION
Cystic kidney diseases represent a heterogeneous group of renal disorders that are defined by the presence of distinctive fluid-filled epithelial sacs in the kidney. The cause of cystic renal diseases can be broadly classified into several categories: inherited, congenital, acquired, or in association with renal malignancies or syndromes ( Fig. 1 ). Of the inherited cystic kidney diseases, autosomal dominant polycystic kidney disease (ADPKD) is the most common, affecting approximately 500 000 individuals (1 : 400-1000 individuals), and is the fourth leading cause of end-stage failure in the United States [1] .
Although the mechanisms underlying cyst formation from existing nephron tubules are complex and remain poorly understood, cyst formation is thought to stem from perturbations in one or more cellular processes such as abnormal cellular proliferation, apoptosis, altered planar cell polarityoriented cell division, or dysfunctional tubular fluid transport [2] [3] [4] [5] [6] . Importantly, disruptions to cilia outgrowth and its downstream signaling cascade have also been implicated in a wide variety of ciliopathies including cystic kidney disease [7] [8] [9] [10] [11] [12] . Irrespective of the underlying cause, the progressive growth and expansion of renal cysts eventually leads to the onset of tubulointerstitial fibrosis and diminishing renal function [13, 14] . Ultimately, patients develop renal failure, requiring either dialysis or renal transplant, resulting in a significant impact on quality of life.
Although previous analyses have successfully identified the causative genes responsible for the onset and inheritance of some cystic kidney diseases such as PKD1 (ADPKD), PKD2 (ADPKD), polycystic kidney and hepatic disease 1 (PKHD1) [autosomal recessive PKD (ARPKD), hepatocyte nuclear factor-1-beta (HNF-1b), renal cysts and diabetes (RCAD) syndrome], and NPHP1-8 (nephronopthisis) [11, 12, [15] [16] [17] [18] [19] [20] [21] [22] [23] , there is now a growing body of evidence to suggest that dysregulation of post-transcriptional regulation is also associated with the renal cystic phenotype [24,25 && ]. Understanding the mechanisms whereby microRNA (miRNA)mediated post-transcriptional regulation is involved in renal development and disease is important as it lays the foundation for future medical interventions, and potential diagnostic and prognostic biomarkers that may translate into improved healthcare for patients.
THE ROLE AND FUNCTION OF MICRORNAS IN KIDNEY DEVELOPMENT
MicroRNAs are endogenously produced, small noncoding RNAs ($22-nucleotides long) that play an essential role in a wide variety of cellular processes, primarily by fine-tuning gene expression via messenger RNA (mRNA) repression [26] . First transcribed as a primary miRNA (pri-miRNA) by RNA polymerase II, pri-miRNAs are processed sequentially by Drosha into precursor miRNAs (pre-miRNA), and then by Dicer into mature miRNAs during the final biogenesis step [27] [28] [29] (Fig. 2) . The ability for miRNAs to target and bind to the 3'-untranslated region (3'-UTR) of its target mRNAs is dependent largely on a unique 8-bp seed sequence present within the miRNA [31, 32] . Moreover, it is notable that each miRNA is capable of having synergistic effects by targeting multiple transcripts within a single signaling pathway [32] . MicroRNA : mRNA duplex strand binding and formation result in the recruitment of the RNA-induced silencing complex (RISC), which then catalyzes the process of decreased mRNA stability and translation [33] .
In terms of kidney morphogenesis, the indispensable role of miRNAs in normal renal
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Classification of cystic kidney diseases and their associated genetic mutations. Genes and miRNAs that are known to be involved in the cystic kidney phenotype are indicated. Bicc1, bicaudal C homolog 1; miRNA, microRNA. development and cellular maintenance has been demonstrated in multiple transgenic mouse models ( Table 1 ). Renal lineage-specific ablation of Dicer in the sine oculis-related homeobox 2 (Six2 þ ) nephron progenitor compartment resulted in renal hypoplasia accompanied by elevated pro-apoptotic protein Bcl2l11 (Bim) mRNA levels and hence premature depletion of the nephron progenitors due to increased cell death [24, 34] . Loss of miRNAs in the Hoxb7 þ ureteric bud lineage was the first transgenic mouse model to illustrate the functional relevance of miRNAs in cystic kidney disease [35] . Ureteric bud cyst formation was attributed to a primary cilia outgrowth defect, increased cellular proliferation, and enhanced apoptosis ( Fig. 3 ) [24] . Interestingly, loss of miRNAs in proximal tubules had no overt effect on kidney development, but rather is renoprotective against ischemia/reperfusion injury due to reduced tubular apoptosis [40] .
THE INTERPLAY BETWEEN MICRORNAS AND POLYCYSTIC KIDNEY DISEASE
MicroRNA dysregulation has now been associated with a wide spectrum of renal pathophysiology. In the context of cystic kidney diseases, the majority of Renin cell Decreased renin cells accompanied by disrupted blood pressure regulation.
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Bim, BCL2-like 11 (apoptosis facilitator).
studies have implicated miRNAs in the pathogenesis of PKD (ADPKD, ARPKD) [25 && ,42-44] . A major challenge continues to be the identification and validation of miRNA : mRNA targets amidst a complex network of altered signaling pathways in these diseases. In spite of this caveat, multiple bioinformatics tools including TargetScan, miRanda, and microT-CDS have been used with existing mRNA datasets to attempt the prediction of upstream miRNAs based on 3'-UTR sequence alignment base pairing [32, 45, 46] . Such an approach was undertaken during the analysis of Pkd1 À/À mice kidneys, and resulted in the prediction of at least 5000 miRNA-mRNA interactions [47] . Collectively, differentially expressed miRNAs in Pkd1 À/À kidneys, such as miRs-10a, 30a, 96, 126-5p, 182, 200a, 204, 488, and 429, that affect signaling pathways known to be strongly associated with ADPKD, including calcium sensing, Wnt, and Notch signaling, have been successfully identified and validated through quantitative PCR measurements [47] . In an alternative approach undertaken by Pandey et al. [48] , simultaneous screening for both mRNA and miRNA changes in inbred Han:SPRD-cy rat kidneys (which mimics ADPKD in humans) led to the identification of 935 and 30 differentially expressed mRNA and miRNAs, including miRs-21, 31, 128, 147, and 217.
The merit from such transcriptome-wide studies is that they can effectively curate a large cohort and network of miRNA-mRNA interactions which form a comprehensive atlas for conducting future experiments regarding the signaling pathways perturbed by miRNAs in ADPKD. These studies, however, lack the ability to define the mechanisms whereby miRNA dysregulation results in a renal cystic phenotype. Elucidation of these regulatory mechanisms remains dependent on the characterization of specific miRNA-overexpressing or knockout in-vitro or in-vivo models.
THE ROLE OF THE MIR17$92 CLUSTER IN THE ONSET OF POLYCYSTIC KIDNEY DISEASE
The miR-17$92 cluster (which consists of miRs- 17, 18a, 19a, 19b, 20a , and 92a) is the first miRNA mutation associated with a human syndrome -Feingold syndrome -and has been implicated in multiple oncogenic tumors [49, 50] . Although patients diagnosed with Feingold syndrome due to miR-17$92 deletion have no reported renal defects to date, Feingold syndrome associated with v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) mutations have an 18% incidence rate of congenital anomalies of the kidney and urinary tract [51, 52] . miR-92a has also been shown to target von Hippel-Lindau (VHL), a gene that is associated with renal cell carcinoma and VHL syndrome, which is characterized by the formation of cysts in numerous organ systems including the kidney [53] [54] [55] .
The importance of miR-17$92 in renal development was recently illustrated by targeted deletion in nephron progenitors (Six2Cre-miR-17$92 fl/fl ), resulting in renal hypoplasia accompanied by signs of progressive renal disease, including albuminuria, podocyte foot effacement, and glomerulosclerosis during adulthood [56 & ]. Mechanistically, this phenotype was thought to be due, at least in part, to elevated levels of the cyclin-dependent kinase inhibitor p21, which is a mRNA target of miR-17-5p and miR-20a, resulting in decreased nephron progenitor proliferation [57] [58] [59] [60] .
In the context of PKD, the miR-17$92 cluster was found to be consistently up-regulated in four transgenic mouse models of PKD including KspCre-Kif3a flg/flg (a mouse model of ciliopathies), Pkhd1Cre-Pkd2 fl/fl (ADPKD model), Pkhd1 À/À null mice (ARPKD model), and Pkhd1Cre-Hnf1b fl/fl (RCAD model) ( Table 2) 
GENETIC INTERSECTION OF MICRORNAS AND BICC1 IN POLYCYSTIC KIDNEY DISEASE
Apart from the role of the miR-17$92 cluster in PKD, miR-17, miR-125a, and miR-27a have also been implicated in renal cyst formation as modulators of Bicaudal C (Bicc1) function (Table 2) [42, 43] . Bicc1 is a post-transcriptional regulatory protein containing five K-homology domains and a sterile alpha motif (SAM) that regulates mRNA stability and translation [42, 64, 65] . Bicc1-null kidneys have a PKD-like phenotype, and Pkd2 is significantly down-regulated [42] . Interestingly, Pkd2 contains a conserved miRNA binding site for miR-17 [42] . On the basis of morpholino knockdown studies in the Xenopus model, genetic cross-talk between miR-17, Pkd2, and Bicc1 was uncovered, whereby Bicc1 was shown to antagonize the repressive effects of miR-17 on Pkd2 [42] . Hence, in the absence of Bicc1, there is elevated repression of Pkd2 via miR-17, and onset of renal cyst formation in the Bicc1 null mice [42] .
Elevated miR-17 repression of Pkd2 is unlikely to be the sole mediator of renal cyst formation in Bicc1 null mice. Overexpression of a single miRNA from the miR-17$92 cluster, miR-17, did not result in overt renal cyst formation, suggesting that the renal cystic phenotype in Bicc1 À/À mice is likely to be the result of a combination of dysregulated pathways [66] . Bicc1 has also been shown to bind to the mRNA of the cyclic adenosine monophosphate (CAMP)associated enzyme AC6 via its K-homology domains, leading to recruitment of miR-125a, which blocks translation of AC6 protein [43] . Similarly, Bicc1 inhibits PKIa protein translation via miR-27a activity [43] . These findings collectively suggest that several miRNAs play an important role in mediating Bicc1-suppressive activity on renal cyst formation by simultaneously repressing multiple mRNA targets.
MICRORNAS AND AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE
To date, most of the studies linking miRNAs to the pathogenesis of inherited cystic renal diseases have focused on ADPKD. In an experimental PCK rat model of ARPKD, which was used to address the underlying mechanisms of hepatic cystogenesis, miR-15a was found to be reduced in cystic cholangiocytes [61] . A potential mRNA target of miR-15a is Cdc25A -a cell cycle regulatory protein which modulates cellular transition from G1 to S phase [67] . The miR15a:Cdc25A target interaction was validated through three-dimensional (3D) cholangiocyte cell culture, whereby knockdown of miR-15a resulted in elevated levels of Cdc25A protein, and hence enhanced cyst formation in culture [61] . Whether this mechanism is generalizable to renal cyst formation in ARPKD remains unknown.
CYSTS ASSOCIATED WITH WILMS TUMORS: THE POTENTIAL CONTRIBUTION OF LIN28-LET7 TRANSCRIPTIONAL REGULATION?
Cystic nephroma and cystic partially differentiated nephroblastoma (CPDN) are rare cystic variants of pediatric Wilms tumor, for which the underlying genetic causes are not well understood [68] . Recent observations from clinical Wilms tumor samples have implicated the RNA-binding protein LIN28 and the conserved miRNA family LET-7 in the pathogenesis of Wilms tumors. LIN28 (which consists of LIN28A and LIN28B) regulates mRNA transcripts either by inhibiting processing of the LET-7 family or by direct mRNA target-binding [69] [70] [71] .
LIN28B was first identified to be elevated in a subset of clinical Wilms tumor samples [72,73 & ]. Recent exome sequencing of Wilms tumor samples has also uncovered the presence of mutations in DROSHA and DICER1, which result in the impaired processing of tumor-suppressing miRNAs, such as LET-7, and subsequent increased expression of LIN28 [74] . To address whether elevated levels of LIN28 are associated with the onset of Wilms tumor, generation of Lin28 overexpressing transgenic mice [VasaCre-Ef1a STOP fl/fl Lin28a (maternal Cre transmission), inducible Wt1Cre-TetOn LIN28B (doxycycline induction)] showed that overexpression of mouse Lin28a ubiquitously or human LIN28B in the renal intermediate mesoderm lineage led to the formation of renal tumors that were pathologically reminiscent to Wilms tumor [73 & ]. The enforced expression of LIN28B suppresses maturation of Let-7 isoforms, thereby causing up-regulation of Let-7 target genes that are thought to prolong nephrogenesis and aberrant persistence of undifferentiated nephron progenitors in Wilms tumor [73 & ]. Conversely, compound mutants overexpressing LIN28B in conjunction with Let-7g -a Let-7 isoform unaffected by Lin28 processing, ameliorated the LIN28B overexpression effect, thereby indicating that LIN28B acts in part via Let-7 post-transcriptional regulatory mechanisms [73 & ]. Interestingly, cellular-specific overexpression of Lin28 in specific renal cell lineages, or when induced postnatally, did not result in tumor formation [73 & ]. Instead, overexpression of Lin28a or LIN28B in the nephron progenitor lineage and its epithelial derivatives (Six2Cre) or in postnatal day 10 kidneys upon doxycycline induction (Wt1Cre-TetOn LIN28B) led to renal cyst formation ( ]. Such findings are suggestive for a novel paradigm whereby Lin28/ let-7 transcriptional regulation is necessary to prevent ectopic renal cyst formation. It is plausible to speculate that ectopic overexpression of LIN28 in specific nephron epithelium could result in a cystic Wilms tumor phenotype, and be associated with cystic nephroma or CPDN in patients, although this remains to be determined.
TRANSLATION FROM BENCH TO BEDSIDE: CLINICAL ASPECTS OF MICRORNAS IN CYSTIC KIDNEY DISEASES
The potential use of miRNAs as diagnostic and prognostic markers in human cystic kidney diseases is promising given their functional relevance to cyst formation. Additionally, the relative stability of miRNAs in biological fluids such as urine makes them attractive as noninvasive biomarkers [75] . Large-scale clinical studies looking at miRNA expression in patients with cystic kidney disease remain limited. Nevertheless, reappraisal of a publicly available microarray data on Gene Expression Omnibus (GSE7869) [76] , which was initially used to look for mRNA changes in human ADPKD cyst samples, showed up-regulation of MIR143HG and MIR100HG. Enrichment of MIR143 was also independently validated through a separate highthroughput RNA-sequencing of ADPKD patient urine samples [77] , thereby highlighting the concordance of miRNA dysregulation in ADPKD.
At present, there are no specific therapies available for the heterogeneous group of disorders that cystic kidney diseases encompass, although there is emerging evidence that novel therapies that target cyst formation may be beneficial. In this review, recent studies were highlighted that demonstrate the involvement of miRNAs in the pathogenesis of cystic kidney diseases. Targeting appropriate candidate miRNAs may serve as one avenue of exploration for innovative therapies, since anti-miR oligonucleotides have been successfully utilized in mouse model systems to reduce renal injury induced fibrosis [78] .
CONCLUSION
MicroRNAs are increasingly relevant to cystic renal diseases in patients, given the growing body of knowledge regarding the dysregulation of miRNA expression in these diseases, along with the association of specific miRNAs with the pathologic mechanisms of cyst formation. The potential for miRNAs to be used as biomarkers in these diseases is encouraging, but remains in the preliminary stages of investigation. As more insights are gained regarding the mechanisms by which miRNAs drive cyst formation, this may lead to innovative therapies for patients with renal cystic diseases.
